Pharma stocks underperform S&P 500 by 5% in next 6 months

Investor sentiment in pharmaceutical companies will decline due to increased regulatory risk from potential drug pricing reforms. The sector will trail the broader market as pricing pressure looms.

Implied probability (Yes)

60%